ClearCut Medical was established to develop and commercialize its proprietary technology and tools for accurate and effective removal of cancer. ClearCut’s platform technology is based on an innovative new form factor for the use of Magnetic Resonance (MRI) that enables accurate and rapid surface imaging for real-time assessment of tissue microstructure in the operating room. The company’s first product, The ClearSightTM MRI System is focused on breast cancer lumpectomy for intraoperative margin assessment of surgically removed tumors. By providing accurate, real-time and simple margin analysis to the surgeon in the OR, the system is able to significantly improve surgical outcomes and reduce re-excision rates. To date over 400 patients have participated in international, multi-center clinical trials, which have shown excellent accuracy compared to the gold standard final histopathology and the potential to reduce the re-excision rates in breast conserving surgery by 80%. Future applications include other surgical excisions of cancerous tumors and biopsies throughout the body.